<bill session="117" type="s" number="2164" updated="2022-12-31T05:26:42Z">
  <state datetime="2021-06-22">REFERRED</state>
  <status>
    <introduced datetime="2021-06-22"/>
  </status>
  <introduced datetime="2021-06-22"/>
  <titles>
    <title type="official" as="introduced">A bill to provide for certain reforms with respect to the Medicare program under title XVIII of the Social Security Act, and for other purposes.</title>
    <title type="display">Lower Costs, More Cures Act of 2021</title>
    <title type="short" as="introduced">Lower Costs, More Cures Act of 2021</title>
  </titles>
  <sponsor bioguide_id="C000880"/>
  <cosponsors>
    <cosponsor bioguide_id="B001135" joined="2021-06-22"/>
    <cosponsor bioguide_id="D000618" joined="2021-06-22"/>
    <cosponsor bioguide_id="E000295" joined="2021-06-22"/>
    <cosponsor bioguide_id="H001061" joined="2022-09-06"/>
    <cosponsor bioguide_id="M001198" joined="2021-06-22"/>
    <cosponsor bioguide_id="R000584" joined="2021-06-22"/>
    <cosponsor bioguide_id="S001184" joined="2021-06-22"/>
    <cosponsor bioguide_id="T000476" joined="2021-06-22"/>
  </cosponsors>
  <actions>
    <action datetime="2021-06-22">
      <text>Introduced in Senate</text>
    </action>
    <action datetime="2021-06-22" state="REFERRED">
      <text>Read twice and referred to the Committee on Finance.</text>
    </action>
  </actions>
  <committees>
    <committee code="SSFI" name="Senate Finance" subcommittee="" activity="Referral"/>
  </committees>
  <relatedbills>
    <bill session="117" type="s" number="1287" relation="unknown"/>
    <bill session="117" type="h" number="3682" relation="unknown"/>
    <bill session="117" type="s" number="2815" relation="unknown"/>
    <bill session="117" type="h" number="4417" relation="unknown"/>
  </relatedbills>
  <subjects>
    <term name="Health"/>
    <term name="Business records"/>
    <term name="Civil actions and liability"/>
    <term name="Congressional oversight"/>
    <term name="Consumer affairs"/>
    <term name="Department of Health and Human Services"/>
    <term name="Digestive and metabolic diseases"/>
    <term name="Drug safety, medical device, and laboratory regulation"/>
    <term name="Drug therapy"/>
    <term name="Executive agency funding and structure"/>
    <term name="Food and Drug Administration (FDA)"/>
    <term name="Fraud offenses and financial crimes"/>
    <term name="Genetics"/>
    <term name="Government information and archives"/>
    <term name="Government studies and investigations"/>
    <term name="Health care costs and insurance"/>
    <term name="Health care coverage and access"/>
    <term name="Health care quality"/>
    <term name="Health personnel"/>
    <term name="Health promotion and preventive care"/>
    <term name="Health technology, devices, supplies"/>
    <term name="Home and outpatient care"/>
    <term name="Inflation and prices"/>
    <term name="Manufacturing"/>
    <term name="Marketing and advertising"/>
    <term name="Medicaid"/>
    <term name="Medical research"/>
    <term name="Medicare"/>
    <term name="Office of the U.S. Trade Representative"/>
    <term name="Prescription drugs"/>
    <term name="Product development and innovation"/>
    <term name="Public participation and lobbying"/>
    <term name="Trade agreements and negotiations"/>
  </subjects>
  <amendments/>
  <summary date="2022-08-23T14:41:30Z" status="Introduced in Senate">Lower Costs, More Cures Act of 2021

This bill establishes and modifies several programs and requirements to address prescription drug prices, particularly in relation to Medicare and Medicaid.

Among other changes, the bill

 requires the Centers for Medicare &amp; Medicaid Services to publish certain information, as reported by pharmacy benefit managers (PBMs), relating to generic dispensing rates, drug discounts and rebates, and payments between PBMs, health plans, and pharmacies; caps annual out-of-pocket spending under the Medicare prescription drug benefit; allows prescription drug plan sponsors under the Medicare prescription drug benefit to offer additional plans in a region; establishes requirements under the Medicaid Drug Rebate Program for certain gene therapies for which prices are indexed to achieved outcomes; and establishes the position of Chief Pharmaceutical Negotiator in the Office of the U.S. Trade Representative.</summary>
</bill>
